

Oncology Nursing™

U P D A T E

Breast Cancer Edition

Clinical Investigator and Nursing Perspectives
on the Management of Common Cancers

FACULTY INTERVIEWS

Emily Olson, MSN, RN, CNP

Denise A Yardley, MD

EDITOR

Neil Love, MD



Oncology Nursing Update Breast Cancer Edition

A Continuing Nursing Education Audio Series

OVERVIEW OF ACTIVITY

Breast cancer is one of the most rapidly evolving fields in oncology nursing and remains a challenge for many healthcare professionals. Furthermore, recent clinical research gains have made an abundance of treatment options available to patients with breast cancer, and published results from ongoing clinical trials continually lead to the emergence of new therapeutic regimens and changes in the use of existing treatments. To provide oncology nurses with the knowledge, information and strategies they can use to address the disparate needs of patients, this issue of the *Oncology Nursing Update* audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with breast cancer. Upon completion of this CNE activity, oncology nurses should be able to better counsel and educate patients while developing up-to-date approaches for the management of this disease.

PURPOSE STATEMENT

To present the most current research developments in breast cancer and to provide the perspectives of a clinical investigator and nurse practitioner on the diagnosis and treatment of this disease.

LEARNING OBJECTIVES

- Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.
- Develop a plan to manage the side effects associated with systemic therapies to support quality of life and continuation of treatment.
- Recall the recent FDA approval of neoadjuvant pertuzumab, and consider this therapeutic approach when evaluating appropriate patients with HER2-positive early breast cancer.
- Develop an evidence-based algorithm for the initial and long-term treatment of localized and advanced estrogen receptor-positive breast cancer.
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CREDIT DESIGNATION STATEMENT

This educational activity for 1.5 contact hours is provided by Research To Practice during the period of July 2015 through July 2016.

FOR SUCCESSFUL COMPLETION

This is an audio CNE program. This booklet contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website ResearchToPractice.com/ONUBreast115 also includes links to relevant abstracts and full-text articles.

To receive credit, participants should read the learning objectives and faculty disclosures, listen to the CD and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/ONUBreast115/CNE. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 75% or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

This activity is supported by educational grants from Genentech BioOncology and Novartis Pharmaceuticals Corporation.

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

If you would like to discontinue your complimentary subscription to *Oncology Nursing Update*, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

Oncology Nursing™

U P D A T E

FACULTY AFFILIATIONS



Emily Olson, MSN, RN, CNP
Instructor in Oncology
Mayo Clinic, Rochester
Division of Medical Oncology
Rochester, Minnesota



Denise A Yardley, MD
Senior Investigator
Breast Cancer Research
Sarah Cannon Research Institute
Tennessee Oncology PLLC
Nashville, Tennessee

EDITOR



Neil Love, MD
Research To Practice
Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — **Ms Olson** and **Dr Yardley** have no real or apparent conflicts of interest to disclose.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheragnostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

SELECT PUBLICATIONS

- Amiri-Kordestani L et al. **First FDA approval of neoadjuvant therapy for breast cancer: Pertuzumab for the treatment of patients with HER2-positive breast cancer.** *Clin Cancer Res* 2014;20(21):5359-64.
- Baselga J et al. **Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.** *N Engl J Med* 2012;366(6):520-9.
- Baselga J et al. **Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.** *N Engl J Med* 2012;366(2):109-19.
- Desmarais JE et al. **Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.** *J Clin Psychiatry* 2009;70(12):1688-97.
- Fedele P et al. **Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer.** *Crit Rev Oncol Hematol* 2015;94(3):291-301.
- Finn RS et al. **The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study.** *Lancet Oncol* 2015;16(1):25-35.
- Francis PA et al. **Adjuvant ovarian suppression in premenopausal breast cancer.** *N Engl J Med* 2015;372(5):436-46.
- Hurvitz SA et al. **A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.** *Breast Cancer Res Treat* 2013;141(3):437-46.
- Hurvitz SA et al. **Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.** *J Clin Oncol* 2013;31(9):1157-63.
- Krop IE et al. **Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.** *J Clin Oncol* 2015;33(10):1136-42.
- Krop IE et al. **Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA.** *Ann Oncol* 2015;26(1):113-9.
- Nagaraj G et al. **Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.** *Breast Cancer Res Treat* 2015;150(2):231-42.
- Perez EA et al. **Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.** *J Clin Oncol* 2014;32(33):3744-52.
- Piccatt M et al. **Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2.** *Ann Oncol* 2014;25(12):2357-62.
- Swain SM et al. **Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.** *N Engl J Med* 2015;372(8):724-34.
- Swain SM et al. **Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.** *Lancet Oncol* 2013;14(6):461-71.
- Tolaney SM et al. **Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.** *N Engl J Med* 2015;372(2):134-41.
- Verma S et al. **Trastuzumab emtansine for HER2-positive advanced breast cancer.** *N Engl J Med* 2012;367(19):1783-91.
- Wong DJ et al. **Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.** *Ann Trans Med* 2014;2(12):122.

Yardley DA. **Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: Considerations for oncologists.** *Clin Breast Cancer* 2014;14(5):297-308.

Yardley DA et al. **Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.** *Adv Ther* 2013;30(10):870-84.

QUESTIONS (PLEASE CIRCLE ANSWER):

- 1. The Phase III CLEOPATRA trial evaluated a combination of docetaxel and trastuzumab with or without _____ for patients with previously untreated HER2-positive metastatic breast cancer.**
 - a. T-DM1
 - b. Pertuzumab
 - c. Lapatinib
- 2. Which of the following is a potential toxicity of everolimus?**
 - a. Colitis
 - b. Pancreatitis
 - c. Noninfectious pneumonitis
- 3. Which of the following adverse events may be associated with trastuzumab?**
 - a. Cardiotoxicity
 - b. Pneumonitis
 - c. Hepatotoxicity
- 4. Women receiving tamoxifen for the treatment or prevention of recurrence of breast cancer should avoid antidepressants that are metabolized through the CYP2D6 pathway.**
 - a. True
 - b. False
- 5. Common side effects that may be experienced by women receiving aromatase inhibitors include which of the following?**
 - a. Hot flashes
 - b. Loss of bone density
 - c. Joint pain
 - d. Vaginal dryness
 - e. All of the above
- 6. T-DM1-related thrombocytopenia can be managed by dose interruptions.**
 - a. True
 - b. False
- 7. The FDA recently granted accelerated approval to pertuzumab in combination with trastuzumab and docetaxel for the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage breast cancer.**
 - a. True
 - b. False
- 8. T-DM1 is an antibody-drug conjugate that combines a chemotherapy agent called emtansine with _____.**
 - a. Trastuzumab
 - b. Docetaxel
 - c. Paclitaxel

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

	BEFORE	AFTER
Efficacy of everolimus in combination with exemestane for advanced estrogen receptor-positive, HER2-negative breast cancer	4 3 2 1	4 3 2 1
Incidence, prevention and management of side effects associated with T-DM1 in the treatment of HER2-positive breast cancer	4 3 2 1	4 3 2 1
Activity of pertuzumab in the neoadjuvant setting for HER2-positive breast cancer	4 3 2 1	4 3 2 1
Clinical strategies to manage adverse events associated with everolimus	4 3 2 1	4 3 2 1

Practice Setting:

- Academic center/medical school
 Community cancer center/hospital
 Group practice
 Solo practice
 Government (eg, VA)
 Other (please specify).....

Approximately how many new patients with breast cancer do you see per year? patients

Was the activity evidence based, fair, balanced and free from commercial bias?

- Yes No

If no, please explain:

Will this activity help you improve patient care?

- Yes No Not applicable

If yes, how will it help you improve patient care?.....

Did the activity meet your educational needs and expectations?

- Yes No

If no, please explain:

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.....4 3 2 1 N/M N/A
- Develop a plan to manage the side effects associated with systemic therapies to support quality of life and continuation of treatment.4 3 2 1 N/M N/A
- Recall the recent FDA approval of neoadjuvant pertuzumab, and consider this therapeutic approach when evaluating appropriate patients with HER2-positive early breast cancer.....4 3 2 1 N/M N/A
- Develop an evidence-based algorithm for the initial and long-term treatment of localized and advanced estrogen receptor-positive breast cancer.....4 3 2 1 N/M N/A
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer.....4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

What other practice changes will you make or consider making as a result of this activity?

.....

.....

What additional information or training do you need on the activity topics or other oncology-related topics?

.....

.....

Additional comments about this activity:

.....

.....

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

- Yes, I am willing to participate in a follow-up survey.
- No, I am not willing to participate in a follow-up survey.

PART 2 — Please tell us about the faculty and editor for this educational activity

	4 = Excellent	3 = Good	2 = Adequate	1 = Suboptimal	
Faculty	Knowledge of subject matter			Effectiveness as an educator	
Emily Olson, MSN, RN, CNP	4	3	2	1	4 3 2 1
Denise A Yardley, MD	4	3	2	1	4 3 2 1
Editor	Knowledge of subject matter			Effectiveness as an educator	
Neil Love, MD	4	3	2	1	4 3 2 1

Please recommend additional faculty for future activities:

.....

Other comments about the faculty and editor for this activity:

.....

.....

REQUEST FOR CREDIT — Please print clearly

Name:..... Specialty:.....

Professional Designation:

- MD DO PharmD NP CNS RN
- PA Other.....

Street Address:..... Box/Suite:.....

City, State, Zip:.....

Telephone:..... Fax:.....

Email:.....

Signature:..... Date:.....

The expiration date for this activity is July 2016. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/ONUBreast115/CNE.

QID 1424

Oncology Nursing™

U P D A T E

Editor	Neil Love, MD
Director, Clinical Content and CPD/CME	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Editorial	Clayton Campbell Marilyn Fernandez, PhD Gloria Kelly, PhD Kemi Obajimi, PhD Margaret Peng
Creative Manager	Fernando Rendina
Graphic Designers	Tamara Dabney Silvana Izquierdo
Managing Editor	Kirsten Miller
Senior Production Editor	Aura Herrmann
Copy Editors	Margo Harris Rosemary Hulce Pat Morrissey/Havlin Alexis Oneca
Production Manager	Tracy Potter
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Faculty Relations Manager	Stephanie Bodanyi, CMP
Continuing Education Administrator for Nursing	Karen Gabel Speroni, BSN, MHSA, PhD, RN
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com
For CME/CNE Information	Email: CE@ResearchToPractice.com

Copyright © 2015 Research To Practice. All rights reserved.

The compact disc, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the

newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Oncology Nursing™

U P D A T E

Copyright © 2015 Research To Practice.

This activity is supported by educational grants from
Genentech BioOncology and Novartis Pharmaceuticals Corporation.

Research To Practice®

Research To Practice is accredited as a provider of continuing nursing education
by the American Nurses Credentialing Center's Commission on Accreditation.

Release date: July 2015

Expiration date: July 2016

Contact hours: 1.5